Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.55 |
| ▸ | MME | P08473 | 6/20 | 0.52 |
| ▸ | BACE1 | P56817 | 3/20 | 0.51 |
| ▸ | GNPAT | O15228 | 1/20 | 0.50 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8821940 | 0.92 | NAALAD2 (0.64) | NAALAD2MMEBACE1GNPATBACE2 | |
| SCHEMBL29889128 | 0.92 | MME (0.50) | MMEBACE1GNPAT | |
| SCHEMBL29634903 | 0.92 | MME (0.50) | MMEBACE1GNPAT | |
| SCHEMBL29892410 | 0.91 | NAALAD2 (0.67) | NAALAD2BACE1GNPATBACE2 | |
| SCHEMBL30671936 | 0.90 | NAALAD2 (0.55) | NAALAD2MMEBACE1 | |
| SCHEMBL3748615 | 0.90 | NAALAD2 (0.68) | NAALAD2MMEBACE1BACE2 | |
| SCHEMBL29602993 | 0.90 | NAALAD2 (0.68) | NAALAD2MMEBACE1BACE2 | |
| SCHEMBL3732243 | 0.90 | NAALAD2 (0.68) | NAALAD2MMEBACE1BACE2 | |
| SCHEMBL27914476 | 0.90 | NAALAD2 (0.68) | NAALAD2MMEBACE1BACE2 | |
| SCHEMBL2980529 | 0.90 | NAALAD2 (0.68) | NAALAD2MMEBACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4274836-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2023-11-15 | — | — | EP | claimed |
| WO-2022148851-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-07-14 | — | — | WO | claimed |
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| EP-4069727-A1 | PEPTIDES FOR THE TREATMENT OF CANCER AND/OR METASTASIS | BCN Peptides, S.A. (ES) | 2022-10-12 | — | — | EP | disclosed |
| US-20220315554-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-10-06 | — | — | US | disclosed |
| EP-3997104-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315554-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FN1, TPX2 | NAALAD2 403/4885MME 2918/4885BACE1 2744/4885 |
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FN1, TPX2 | NAALAD2 403/4885MME 2918/4885BACE1 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.